The impacts of supplementing the diet of gestating gilts twice daily with 4 g of the plant extract silymarin on circulating hormonal concentrations, oxidative status, mammary development, and mammary gene expression at the end of gestation were determined. Gilts were fed conventional diets during gestation and on d 90 they were assigned as controls (CTL; n = 16) or treated (TRT; n = 17) animals. Treatment consisted of providing 4 g of silymarin twice daily until d 110, at which time all gilts were slaughtered to collect mammary tissue for compositional analyses and measures of gene expression and oxidative status, and liver and corpora lutea for measures of oxidative stress variables. Blood samples for hormonal assays and evaluation of oxidative stress biomarkers were obtained on d 89, 94, and 109 of gestation. Silymarin increased (P = 0.05) circulating concentrations of prolactin over all samples in the repeated in time analysis. In separate analyses for each sampling time, prolactin concentrations in TRT gilts tended (P < 0.10) to be greater than in CTL gilts on d 94 of gestation. Repeated in time analysis also revealed that silymarin reduced (P ≤ 0.05) plasmatic accumulation of biomarkers of oxidative damage to protein (protein carbonyls) between d 89 and 109. There was no effect (P > 0.10) of treatment on progesterone, estradiol, leptin, or 8-hydroxy-2'-deoxyguanosine concentrations. Percent fat in mammary parenchyma was greater (P ≤ 0.05), percent protein was lesser (P ≤ 0.05), and concentrations of both RNA (P ≤ 0.01) and DNA (P < 0.05) were lesser in TRT than CTL gilts. Mammary parenchyma from TRT gilts had lower (P ≤ 0.05) mRNA abundance for STAT5A and leptin and tended to have lower (P ≤ 0.10) abundance for STAT5B than CTL gilts. Silymarin reduced (P ≤ 0.001) protein carbonyls concentrations in liver of TRT gilts. No effect of treatment was observed on antioxidant gene expression and enzymatic activities in liver samples while total superoxide dismutase activity tended to be higher (P ≤ 0.10) in the corpora lutea of TRT animals when compared with CTL. This is the first demonstration that, in female pigs, silymarin can increase prolactin concentrations and protect against oxidative stress, yet the increase in prolactin was not enough to have beneficial effects on mammary gland development in late gestation.
INTRODUCTION
The growth rate of suckling piglets is largely determined by sow milk yield, but sows cannot produce enough milk to sustain optimal growth of their litter (Miller et al., 2012) . One avenue to increase sow milk yield would be to stimulate mammary development in late gestation. Prolactin is essential for mammogenesis, which occurs in the last third of pregnancy in swine (Farmer et al., 2000; Farmer and Petitclerc, 2003) , and exogenous prolactin affects mRNA expression for both prolactin and its receptor in mammary tissue (Farmer and Palin, 2005) . Hyperprolactinemia in late-pregnant gilts, using a dopamine antagonist, was recently found to stimulate mammary development and subsequent milk yield (VanKlompenberg et al., 2013 ). Yet the use of a pharmaceutical drug for standard management practices is not a possible avenue for commercial swine operations. The plant extract silymarin (from Silybum marianum, generally known as milk thistle) was found to significantly increase prolactin concentrations in female rats (Capasso et al., 2009) and to also increase milk production in cows (Tedesco et al., 2004) . Silymarin was notably used in alternative medicine to increase milk yield in women with hypogalactia (Di Pierro et al., 2008) . Silymarin provided per os at doses of 1, 2, or 4 g/d did not increase circulating concentrations of prolactin in postweaned multiparous sows but the lack of effect on prolactin could have been due to too low a dose (Loisel et al., 2013) . Silymarin is also widely known for its hepatoprotective, anti-inflammatory, and antioxidant properties (Gupta et al., 2000; Giese, 2001; Wu et al., 2011) . Such properties could be of great interest for gestating gilts knowing that oxidative stress conditions occurring during the periparturient period are related to increased health disorders and poor litter performance (Al-Gubory et al., 2010) . The objectives of the current project were to determine if a dose of 8 g/d of silymarin fed for 21 d can stimulate prolactin secretion, mammary development, and mammary gene expression, and alleviate oxidative stress conditions in late-pregnant gilts.
MATERIALS AND METHODS
Animals were cared for according to a recommended code of practice (Agriculture and Agri-Food Canada, 1993) and procedures were approved by the institutional animal care committee.
Animals and Treatments
Thirty-three Yorkshire × Landrace gilts were bred via artificial insemination using a pool of semen from Duroc boars. They were housed in individual gestation pens (1.5 by 2.4 m) and were fed 2.5 kg daily of a 13% CP (3,150 kcal/kg DE and 0.53% Lys) commercial diet until d 25 of gestation. From d 26 until 70 of gestation, they were fed at a rate of 2.6, 2.4, or 2.1 kg/d for gilts with backfat thicknesses of <16 mm, 16 to 18 mm, and >18 mm. From d 70 to 90 of gestation, they were all fed 2.5 kg of the same diet, and from d 90 to 110 of gestation, they were all fed 3.2 kg daily. During this last period only, the diet was provided in 2 daily meals, namely 2.0 kg in the morning and 1.2 kg in the afternoon. Gilts were assigned either as controls (CTL; n = 16) or treated (TRT; n = 17), the treatment consisting of dietary supplementation with 4 g of silymarin twice daily (at 0830 and 1445 h) from d 90 until 110 of gestation. Silymarin BIO-C is a standardized plant extract consisting of 49.4% silybin, 15.2% isosilybin, and 35.4% silydianin plus silychristin and was provided from Indena S.p.A. (Milan, Italy) . The silymarin was mixed with 13 g of crushed corn and 12 mL of water and given before the normal daily ration. Control gilts received the corn-water mixture alone.
Gilts were weighed and had their backfat thickness measured ultrasonically at P2 of the last rib (Vetkoplus; NOVEKO, Lachine, Canada) at mating and on d 89 and 109 of gestation. Jugular blood samples were obtained on d 89, 94, and 109 of gestation. The sample on d 89 represented baseline values (before onset of treatment) and that on d 109 represented end of treatment values. A sample was also collected on d 94 to ensure that any short-term response in prolactin would be detected. This was based on a preliminary trial (cited in Loisel et al., 2013 ) using 3 treated and 3 control sows, where there was an increase in prolactin concentrations after 2 to 3 d of feeding silymarin in late gestation. All gilts were slaughtered on d 110 of gestation to obtain mammary glands for compositional analyses and samples of parenchymal tissue for gene expression analyses. Their uterus was removed and fetuses were counted and weighed; ovaries were also obtained and weighed, and the number of corpora lutea was counted. Samples from the left lateral lobe of the liver, mammary glands, and corpora lutea were collected for ulterior measures of oxidative status. Tissues collected for gene expression and oxidative status analyses were put in liquid nitrogen and frozen at -80°C. The experiment took place between June and December 2011.
Blood Handling and Assays
Blood samples (30 mL) were used to determine concentrations of prolactin, progesterone, estradiol, and leptin. Blood sampling was done before the morning feeding (which was at 0850 h) and samples for estradiol analyses were collected in EDTA tubes (Becton Dickinson and Cie, Rutherford, NJ), while those for other hormonal analyses were collected into tubes without anticoagulant. Samples for estradiol were put on ice and centrifuged within 20 min at 4°C for 12 min at 1,800 × g, and plasma was immediately recovered and frozen at -20°C until assayed. Other blood samples were left at room temperature for 4 h, stored overnight at 4°C, and centrifuged the following day at 4°C for 12 min at 1,800 × g, and serum was harvested. Concentrations of prolactin were determined according to a previously described RIA (Robert et al., 1989) . The radioinert prolactin and the first antibody to prolactin were purchased (A. F. Parlow, U.S. National Hormone and Pituitary Program, National Institute of Diabetes and Digestive and Kidney Diseases, Torrence, CA). Validation for a plasma pool from lactating sows was conducted. Parallelism was 96.6% and average mass recovery was 98.9%. Sensitivity of the prolactin assay was 1.5 ng/mL. The intra-and interassay CV were 3.50 and 5.04%, respectively. Progesterone (ICN Pharmaceuticals Inc., Costa Mesa, CA) and estradiol (Diagnostic Systems Laboratories Inc., Webster, TX) were quantified using commercial RIA kits. Intra-and interassay CV were 4.19 and 3.82%, respectively, for progesterone and 3.74 and 4.06%, respectively, for estradiol. Assay sensitivity was 0.2 ng/mL for progesterone and 4 pg/mL for estradiol. Serum concentrations of leptin were determined with a multispecies double-antibody RIA kit assay (Millipore, St. Charles, MO) validated in pigs. The intraassay and interassay CV were 6.48 and 4.93%, respectively, and sensitivity was 1 ng/mL.
Mammary Gland Measurements
At slaughter, mammary glands from one side of the abdominal wall were excised and stored at -20°C until dissection and analyses for tissue composition. Frozen mammary glands were trimmed of skin and teats and subsequently stored at -20°C. They were then sawed into 2-cm slices and mammary parenchymal tissue from each slice was dissected from surrounding adipose tissue (i.e., extraparenchymal tissue) at 4°C and both parenchymal and extraparenchymal tissue weights were recorded. For each gilt, parenchymal tissue from all dissected and sliced glands was homogenized and a representative sample was used for determination of composition by chemical analysis. The DNA content of parenchymal tissue was evaluated in all samples using a method based on fluorescence of a DNA stain (Labarca and Paigen, 1980) and the RNA content of parenchymal tissue was measured by ultraviolet (Volkin and Cohn, 1954) . Dry matter, protein, and lipid contents were also determined (AOAC, 2005) in parenchyma. Parenchymal tissue samples from the fourth teat of the other half mammary gland were also collected from 8 CTL and 8 TRT sows for determination of oxidative status and measurement of relative mRNA abundance for prolactin (PRL), the long form of the prolactin receptor (PRLR-LF), signal transducers and activators of transcription 5A (STAT5A), STAT5B, whey acidic protein (WAP), leptin (LEP), nuclear factor-erythroid 2-related factor 2 (NRF2), peroxisome proliferator-activated receptor γ 1 (PPARG1), and peroxisome proliferative activated receptor, γ, coactivator 1 α (PPARGC1a).
Ribonucleic Acid Extraction, Complementary DNA Synthesis, and Real-Time PCR Amplifications of Studied Genes
Total RNA was extracted from parenchymal tissue and reverse transcribed as previously described (Labrecque et al., 2009) . The relative mRNA abundance of studied genes in mammary parenchymal tissue (PRL, STAT5A, STAT5B, WAP, LEP, NRF2, PPARG1, and PPARGC1a) and liver (glutathione peroxidases 1 and 4 [GPx1 and GPx4] and superoxide dismutases 1 and 2 [SOD1 and SOD2]) was determined using real-time PCR amplifications. Primer sequences for PRL, LEP, NRF2, PPARG1, and PPARGC1α are shown in Table 1 and those for PRLR-LF, STAT5A, STAT5B, and WAP were previously reported (Farmer et al., 2012) . Primers were designed using the Primer Express software 3.0 (PE Applied Biosystems, Foster City, CA). The PCR amplifications were performed in a 10-μL reaction volume consisting of the predetermined optimal concentration of both forward and reverse primers (Table 1; Farmer et al., 2012) , 5 μL of 2x Power SYBRGreen Master Mix (PE Applied Biosystems), 3 μL of 15 × diluted cDNA, and 0.05 μL of Uracil N-glycosylase AmpErase (PE Applied Biosystems). Cycling conditions, detection, and data analysis were performed as previously described (Labrecque et al., 2009 ). Specificity of amplified fragments was verified with the melting curve analysis (Dissociation Curves v1.0; PE Applied Biosystems). Four reference genes were amplified to identify the 1 that was the least affected by treatments. These reference genes are peptidylprolyl isomerase A (PPIA), β-actin (ACTB), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and ubiquitin C (UBC; Farmer et al., 2012; Table 1 ). Amplifications were performed in triplicate and standard curves were established in duplicate for each gene. Standard curves were composed of serial dilutions of complementary DNA pools (Labrecque et al., 2009 ) and were used to obtain the relative quantification of mRNA using the standard curve method as described in User Bulletin 2 (Applied Biosystems, 1997). Relative quantification values were then normalized using PPIA and ACTB reference genes, which were the least affected by treatment (P > 0.10) according to the NormFinder statistical algorithm (Andersen et al., 2004) . For each experimental sample, the amount of the studied genes relative to PPIA and ACTB mRNA was determined from their respective standard curves. Relative quantity ratios were obtained by dividing the relative quantity units of the studied genes by the average amount of PPIA and ACTB. Mean values from triplicates were used to perform the statistical analyses.
Determination of Oxidative Damage and Antioxidant Potential
The evaluation of oxidative damage to proteins (protein carbonyl content) in plasma and liver samples was determined with the OxiSelect Protein Carbonyl ELISA Kit (Cell Biolabs INC, San Diego, CA) according to the manufacturer's instructions, as described by Neretti et al. (2009) , with minor modification for liver samples. Briefly, 200 to 300 mg of liver samples were rinsed and homogenized in 50 mM phosphate buffered saline solution pH 6.7 containing 1 mM EDTA and were centrifuged at 10,000 × g for 10 min at 4°C. Supernatants were then collected and directly assayed for carbonyl content according to the provided protocol. The plasmatic concentration of 8-hydroxy-2'-deoxyguanosine (8-OHdG), a biomarker for oxidative damage to DNA, was measured using an enzyme-linked immunoassay kit according to the manu-facturer's protocol (Cedarlane Labs, Burlington, ON) as previously performed (Lapointe et al., 2009 ). The specific activity of aconitase, an enzyme known to be highly sensitive to oxidative stress and frequently used as a marker of mitochondrial oxidative damage, was determined in isolated mitochondria from both liver and mammary glands using the Aconitase Activity Kit (Cayman Chemical, Ann Arbor, MI) as previously described (Dumont et al., 2011) . Aconitase activity was expressed as the amount of citrate metabolized to isocitrate (in nmol) in 1 min by following the increase in absorbance at 340 nm associated with the formation of nicotinamide adenine dinucleotide phosphate and normalized to milligrams of soluble protein. Liver and mammary gland mitochondria were isolated by standard differential centrifugation according to previously detailed procedures (Lapointe and Hekimi, 2008) . Total superoxide dismutase (SOD) activity was measured in whole tissue homogenate from corpora lutea and liver using a commercially available kit (Cayman Chemical, Ann Arbor, MI) according to the provided instructions and as described in Lapointe et al. (2009) . All activities were normalized to the quantity of proteins used in the assays.
Statistical Analyses
The MIXED procedure of SAS (SAS Inst. Inc., Cary, NC) was used for statistical analyses. The univariate model used for mammary gland composition, mRNA abundance, and enzymatic activities as well as oxidative damage to proteins and DNA included the effect of treatment, with the residual error being the error term used to test main effects of treatment. Repeated measures ANOVA with the factors treatment (the error term being sow within treatment) and day (the residual error being the error term) and the treatment × day interaction were performed on sow backfat, BW, and hormonal data. The slice option was used to determine effects at each time. Data were corrected with a logarithmic transformation (using natural logarithms) when data distribution was not normal (as verified with the Shapiro-Wilk test). This transformation also corrects for any problems of nonhomogeneous variances. Data in tables and figures are presented as least squares means ± maximal SEM.
RESULTS
The BW and backfat thickness of gilts used in the study are shown in Table 2 and were similar across treatments. There was no effect (P > 0.10) of treatment on weight of the ovaries (left: 12.15 ± 3.59 and right: 11.02 ± 2.67) or number of corpora lutea (left: 9.58 ± 3.73 and right: 8.52 ± 2.97) at slaughter. Furthermore, the number of fetuses (13.9 vs. 12.7 ± 0.7 for CTL and TRT gilts, respectively) and average BW of fetuses (1.19 vs. 1.23 ± 0.39 kg for CTL and TRT gilts, respectively) were not affected (P > 0.10) by treatment. Circulating concentrations of hormones 1 GPx1 and GPx4 = glutathione peroxidases 1 and 4; SOD1 and SOD2 = superoxide dismutases 1 and 2; ACTB = actin, beta; LEP = leptin; PRL = prolactin; NRF2 = nuclear factor-erythroid 2-related factor 2; PPARG1 = peroxisome proliferator-activated receptor gamma 1; PPARGC1a = peroxisome proliferative activated receptor, gamma, coactivator 1 alpha.
2 F = forward primer; R = reverse primer.
are shown in Table 3 . The repeated in time analysis showed an effect (P = 0.05) of treatment on prolactin concentrations, with values being greater in TRT than CTL gilts. Analyses at each sampling time revealed a tendency for prolactin to be greater in TRT than CTL gilts on d 94 of gestation only. There was no effect (P > 0.10) of treatment on progesterone, estradiol, or leptin concentrations but there was a day effect (P < 0.01) for all hormones determined. Values for prolactin and estradiol increased with advancing gestation, whereas those of progesterone decreased and those of leptin were greatest on d 94 of gestation (Table 3) . Mammary gland composition and relative mRNA abundance of selected genes on d 110 of gestation are shown in Table 4 . Percent fat in mammary parenchyma was greater (P ≤ 0.05), percent protein lesser (P ≤ 0.05), and concentrations of both RNA (P ≤ 0.01) and DNA (P < 0.05) lesser in TRT than CTL gilts. There were tendencies for the DM percent and the protein:RNA ratio in parenchyma to be increased (P < 0.10) with treatment. Results on mammary relative mRNA abundance showed lesser expression (P < 0.05) of the LEP and STAT5A genes and a tendency for lower expression (P < 0.10) of the STAT5B gene in TRT than CTL animals. Expression of mitochondrial biogenesis-related genes revealed that the expression of the NRF2 gene was lesser (P < 0.05) and that of PPARGC1a tended to be greater (P < 0.10) in mammary parenchyma from TRT compared with that of CTL gilts.
Data on measures of oxidative status in plasma and various tissues are shown in Table 5 . There was no effect (P > 0.10) of silymarin supplementation on concentrations of the principal biomarkers of oxidative damage to proteins (carbonyls) and DNA (8-OHdG) in plasma samples on d 89 and 109 of gestation. However, the repeated in time analysis showed an effect (P < 0.05) of treatment on plasmatic protein carbonyls concentrations, with values being lesser in TRT than CTL gilts. Analyses of oxidative damage to liver revealed that protein carbonyl concentrations were reduced (P < 0.001) in treated compared with CTL gilts. The activities of the oxidative stress-sensitive enzyme aconitase and the major mitochondrial SOD were not affected (P > 0.10) by silymarin in isolated mitochondria or whole liver homogenates. Additionally, mRNA expression of genes encoding for the major hepatic antioxidants (SOD1, SOD2, GPx1, and GPx4) was similar (P > 0.10) between TRT and CTL gilts. The activity of aconitase was not affected (P > 0.10) by silymarin in isolated mitochondria from mammary parenchyma and there was a tendency for the activity of SOD in corpora lutea to be increased (P < 0.10) with silymarin.
DISCUSSION
This is the first report that the plant extract silymarin can increase circulating concentrations of prolactin and alleviate oxidative stress conditions in swine. Earlier findings using doses of 1, 2, or 4 g/d per os showed no increase in prolactin concentrations of postweaned multiparous sows (Loisel et al., 2013) . On the other hand, recent unpublished data (cited in Loisel et al., 2013) using a very small number of prepartum gilts (3 treated and 3 controls) showed that feeding 8 g/d of silymarin from d 111 of gestation until farrowing increased circulating prolactin concentrations 24 h before farrowing (P < 0.05). A greater dose was not used because cost would make it prohibitive for producers to use on a regular basis.
Furthermore, a dose of 4 g/d for a 250 kg BW sow is almost equivalent to the 10 g/d given to cows (approximate BW of 600 kg) by Tedesco et al. (2004) , where positive effects on milk yield were seen. It is therefore not known whether a greater dose would have brought about a more important increase in prolactin concentrations, but this is likely because Capasso et al. (2009) c,d Means within a row with different superscripts tend to differ (P ≤ 0.10).
1 Maximum value.
2 Tendency for treatment × day effect in the repeated measures analysis, P < 0.10.
3 8-OHdG = 8-hydroxy-2'-deoxyguanosine.
4 SOD = superoxide dismutase.
5 Relative mRNA abundances (n = 8 for CTL and n = 8 for TRT). Values correspond to the relative abundance of studied genes mRNA. GPx1 and GPx4 = glutathione peroxidases 1 and 4; SOD1 and SOD2 = superoxide dismutases 1 and 2. e,f Means within a row with different superscripts tend to differ (P ≤ 0.10).
2 Expressed on a DM basis.
3 Relative mRNA abundances (n = 8 for CTL and n = 8 for TRT). Values correspond to the relative abundance of studied genes mRNA. PRL = prolactin; PRLR-LF = long form of the prolactin receptor; STAT5A and STAT5B = signal transducers and activators of transcription 5A and 5B; WAP = whey acidic protein; LEP = leptin; NRF2 = nuclear factor-erythroid 2-related factor 2; PPARG1 = peroxisome proliferator-activated receptor gamma 1; PPARGC1a = peroxisome proliferative activated receptor, gamma, coactivator 1 alpha. et al., 2011) . Analyses of the expression of major genes implicated in mitochondrial biogenesis (NRF2, PPARG1, and PPARGC1a) in the current study suggest that silymarin had no significant effect on this process in mammary glands of treated gilts. Indeed, while we observed that the master regulator of mitochondrial biogenesis related genes, PPARGC1a, tended to be slightly upregulated by the treatment, the mRNA expression of its downstream coregulators NRF2 and PPARG1 were found to be either significantly repressed or unaffected. Additional works are required to better characterize the interaction between those regulatory genes in response to silymarin.
The observed decrease in STAT5A and STAT5B mRNA abundance was unexpected as there was no difference in parenchymal tissue weight between TRT and CTL animals. In a previous study, we rather observed positive correlations between STAT5B mRNA abundance and mammary parenchymal weight in Large White gilts on d 100 of gestation (Palin et al., 2002) . Moreover, gilts that were subjected to diet deprivation followed by overallowance during puberty had less parenchymal tissue and this was followed by a decrease in STAT5B mRNA abundance (Farmer et al., 2012) . Although STAT5A and STAT5B are well-known mediators of prolactin signal transduction, the increase in circulating prolactin on d 94 of gestation is unlikely to be related with the observed decrease in mRNA levels since it was previously reported that prolactin injections to prepubertal gilts rather increase the mRNA abundance of both STAT5A and STAT5B in the parenchyma (Farmer and Palin, 2005) . In that same trial, providing exogenous prolactin for a period of 28 d decreased mRNA levels for PRL in mammary parenchyma as well as in anterior pituitary tissue, reflecting a negative feedback. The absence of such an effect in mammary tissue in the current trial could be due to the much smaller and shorter duration of the increase in circulating prolactin concentrations compared with that seen in the study by Farmer and Palin (2005) . Accordingly, no effects were seen on mRNA abundance for the PRLR-LF gene. Nevertheless, additional work is needed to verify whether the effects of silymarin on STAT5A and STAT5B mRNA abundance are repeatable and independent of its effect on prolactin.
The first indication that leptin might be involved in mammary gland development was provided by leptindeficient obese mice (ob/ob) that had near-complete absence of mammary epithelial development (Hu et al., 2002) . The presence of LEP and leptin receptor transcripts in mammary parenchymal tissue from gilts and the positive association between parenchymal tissue weight and LEP mRNA abundance in Upton-Meishan gilts further suggested a putative role for leptin in mammary gland development (Palin et al., 2004 ). In the current study, there was a decrease in LEP mRNA abundance in the mammary parenchymal tissue of TRT gilts, but this was not accompanied by decreases in parenchymal weight or in circulating concentrations of leptin. Therefore, the mechanism through which silymarin affects LEP transcription in mammary parenchyma remains to be determined.
The absence of beneficial impact of silymarin on mammary development and gene expression may be due to the fact that prolactin concentrations were not increased enough or for a long enough period of time to exert a biological effect. Indeed, in the study by VanKlompenberg et al. (2013) , where a significant effect of increased prolactin concentrations in late gestation was seen on secretory activity of mammary parenchyma and mammary epithelial cell differentiation in gilts, prolactin concentrations were increased almost 4-fold within 24 h of treatment and remained greater for 6 d. In the present project, there was no blood sampling 24 h posttreatment so it is not known if prolactin concentrations peaked earlier.
Comparison between the 2 studies in terms of mammary development is somewhat difficult because different variables were measured. On the one hand, no measures of mammary composition were obtained in the study of VanKlompenberg et al. (2013) and, on the other hand, no histological work was done in the current study. It is therefore not known whether changes may have occurred at the cellular level, which could have impacted subsequent lactation performance, as was the case in the study of VanKlompenberg et al. (2013) . Indeed, cell culture work showed a positive effect of silymarin on mammary cell growth and differentiation in rodents and dairy cows, and this effect was dependent on the dose (Starvaggi Cucuzza et al., 2010) . Because gilts were slaughtered at the end of gestation in the current study, it is not known whether postpartum gene expression could have been modulated. It is important to mention, however, that the treatment used by VanKlompenberg et al. (2013) was the pharmacological agent domperidone, a dopamine antagonist, which would not be a possible tool for producers to use on a regular basis. On the other hand, silymarin would be an interesting feed additive in swine production because it is a natural bioactive compound, which was found to have very low toxicity and rare adverse health effects (review by Dixit et al., 2007) .
Even though it was demonstrated in vitro that the protein from silymarin is easily digested by pepsin and trypsin (Zhu et al., 2013) , another possibility for the absence of effects of silymarin on mammary development could be its poor absorption. The low bioavailability of silymarin for targeted tissues, such as mammary glands, therefore necessitates either the use of large doses to achieve therapeutic plasmatic concentrations or complexation with specific molecules to increase its solubility and gastric absorption (Dixit et al., 2007) .
Silymarin is widely known for its hepatoprotective and antioxidant properties in numerous species (Saller et al., 2001; Wu et al., 2011 ) and current results demonstrate that this is also the case in gestating gilts. Silymarin decreased the liver protein carbonyl content without affecting mitochondrial oxidative status and gene expression of the principal cellular antioxidants. Similar actions of silymarin on protein carbonyls were also observed in rodents (Kiruthiga et al., 2007; Turgut et al., 2008) . Interestingly, the current study also showed that silymarin has an impact on systemic oxidative stress conditions by reducing the accumulation of circulating protein carbonyls from d 89 to d 109 of gestation. Taken together, these results indicate that silymarin decreased the levels of oxidative damage in liver and plasma but that this effect was not modulated by endogenous antioxidants. Additional work is needed to fully identify the mechanisms underlying the antioxidant properties of silymarin in gestating gilts but it is evident that such effects would be highly beneficial. Indeed, the increased liver energy metabolism and oxidative stress conditions that normally occur during the periparturient period are known to be associated with various physiological disorders as well as poor litter performance (Al-Gubory et al., 2010) .
The potential of silymarin to alleviate oxidative stress seems to be restricted to the liver as no significant effects were observed at the level of the mammary glands or corpora lutea. It is possible that greater concentrations of silymarin or utilization of a specific vehicle to facilitate its absorption may be required to positively affect oxidative status in other organs. However, the observed tendency toward an increase in total SOD activity in corpora lutea is of interest considering that SOD were shown to be activated by prolactin in the rat corpus luteum (Sugino et al., 1998) . This suggests that the increased circulating prolactin concentrations measured 4 d after the onset of the silymarin treatment may have induced SOD activity in these particular endocrine structures.
In conclusion, providing 8 g/d per os of the plant extract silymarin transiently increased circulating concentrations of prolactin in late-pregnant gilts but this increase was not large enough to positively influence mammary development or gene expression. Yet silymarin at this dosage did alleviate oxidative stress conditions, which could be beneficial, especially in the highly stressful periparturient period.
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